Drug Profile
Research programme: apoptosis stimulants - Ascenta
Alternative Names: SH-122; SM-122; SM-164; Smac-mediated cancer therapy - AscentaLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Ascenta Therapeutics
- Class Small molecules
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 14 Sep 2009 Preclinical development is ongoing in USA
- 26 Mar 2009 Pharmacokinetics & pharmacodynamics data from preclinical trials in Cancer presented at the 237th American Chemical Society National Meeting (ACS-2009)